Alzheimer’s disease Therapeutics and Diagnostics Market Overview
Alzheimer’s disease (AD) is the most regular cause of progressive dementia in the elderly populace. There has been an exponential increase in the frequency of Alzheimer’s disease cases globally, stressing the need to develop an effectual treatment to cure it.
Presently, very few therapeutic options are present in the market and none of them offer a complete remedy for this condition. Hence, entry into the market would provide lucrative growth prospects to the industry players.
The growth of the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is mainly driven by factors such as growing old age population, rising R&D investment, high frequency of Alzheimer’s and neurodegenerative diseases, and improved life expectancy of the general population. However, factors such as the astronomical cost of treatment and lack of proper reimbursement policies are preventing the growth of the market.
Alzheimer’s disease Therapeutics and Diagnostics Market Forecast Report (2018-2023)
According to the Research Report, the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is published by the Market Data Forecast. The market was worth USD 10790 Million in 2018 and estimated to be growing at a CAGR of 4.62%, to reach USD 13823 Million from the forecast period 2018 to 2023
Browse Report Brief and TOC @ https://www.marketdataforecast.com/market-reports/global-alzheimers-disease-therapeutics-and-diagnostics-market-2247/
Alzheimer’s disease Therapeutics and Diagnostics Market Segmentation
The Global Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics, is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the global Alzheimer’s Disease Therapeutics and Diagnostics market are segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the global Alzheimer’s disease Therapeutics and Diagnostics market. The absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share
The market has also been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America is anticipated to be the largest market for Alzheimer’s disease Therapeutics and Diagnostics due to the growing prevalence of Alzheimer’s disease and extensive technological developments in the region. With the rise in aging populace in the developing region of Asia Pacific, this market is projected to grow at the highest CAGR during the forecast period.
The major companies dominating this market for its products and services are
- Abbvie Inc.,
- Pfizer Inc.,
- AC Immune SA,
- Eisai Co Ltd.,
- Allergen PLC,
- Novartis AG,
- Amarantus Bioscience Holdings,
- H. Lundbeck A/S,
- Anavex LifeSciences,
- Avid Radiopharmaceuticals,
- Forest Laboratories Inc.,
- Axon Neuroscience,
- Daiichi Sankyo Co,
- TauRx Therapeutics Ltd,
- Eli Lilly, F. Hoffmann La Roche AG,
- Johnson & Johnson,
- GE Healthcare,
- Janssen Pharmaceuticals
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Sales Manager at Market Data Forecast